Please assess the completion status of the following clinical trial:

Trial Title: Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas~2. Stage I or II disease (clinical stage T1-3, N0-1, M0 by AJCC staging criteria).~3. Successful surgical resection~   * Complete resection (R0) or with microscopic residual disease (R1)~  * Expected to receive gemcitabine monotherapy as adjuvant chemotherapy~4. Laboratory Values:~   * Absolute neutrophil count ≥ 1.5 x 10\^9/l~  * Platelets ≥100 x 10\^9/l~  * Haemoglobin ≥ 9 g/dl~  * Total bilirubin ≤ 1.5 x UNL~  * Serum creatinine ≤ 1.5 x UNL~  * Albumin ≥ 2.5 g/dl~  * AST or ALT ≥ 5 x UNL~5. 18 years of age or older.~6. ECOG performance status (PS) of 0-1.~7. Life expectancy of at least 6 months~8. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy~9. Provide written (signed) informed consent to participate in the trial prior to any trial specific screening procedures~Exclusion Criteria:~1. Has received an investigational drug within 4 weeks prior to Trial drug administration~2. Has received previous therapy for pancreatic cancer including radiation or chemotherapy (except for the primary resection or primary neoadjuvant chemotherapy).~3. Is currently receiving any agent with a known effect on the immune system, unless at dose levels that are not immunosuppressive (e.g. Prednisone at 10 mg/day or less or as inhaled steroid at doses used for the treatment of asthma).~4. Has any other serious illnesses or medical conditions such as, but not limited to:~   * Any uncontrolled infection~  * Uncontrolled cardiac failure classification III or IV (NY Heart Association)~  * Uncontrolled systemic and gastro-intestinal inflammatory conditions~  * Bone marrow dysplasia~  * History of auto-immune disease~  * History of adverse reactions to vaccines~5. Known history of positive tests for HIV/AIDS, hepatitis B or C~6. Pregnant or lactating females or have no pregnancy test at baseline (postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential).~7. Contraindication to gemcitabine treatment~8. Have had any other malignancies within last 3 years (except for adequately treated carcinoma of the cervix or basal or squamous cell skin cancer)~9. Known malignant brain lesion(s)~10. Are unlikely to start chemotherapy within 12 weeks of surgery (e.g. delayed wound healing, or infection, etc.)~11. Are not expected to complete 6 cycles of chemotherapy~12. Are planned to receive yellow fever or other live (attenuated) vaccines during the course of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- TG01/GM-CSF and Gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete